A Medical Device Daily
Haemonetics (Braintree, Massachusetts) has entered into a reagent development and supply agreement with Quotient Biodiagnostics Group (Newtown, Pennsylvania) and its wholly owned subsidiary Alba Bioscience (Edinburgh, Scotland). This arrangement provides Haemonetics with exclusive access to Alba's catalogue of approved reagents for use in connection with the commercialization of its Arryx laser based blood typing platform.
The arrangement includes future milestone payments in connection with the optimization of reagents for use in the Arryx system. Access to the reagents for commercialization is provided through a perpetual license. Other terms were not disclosed.
Brian Concannon, Haemonetics' president/CEO, said, “Blood typing represents a future $1 billion market opportunity for Haemonetics through the ongoing development of our Arryx technology. I am pleased to report this important milestone in our innovative nanotechnology development program targeted at the blood diagnostics market.“
Paul Cowan, chairman of Quotient Biodiagnostics, said, “We are pleased to be working with Haemonetics on this exciting new technology platform for the transfusion diagnostics market. Alba's portfolio of world-leading blood typing reagents will no doubt serve to facilitate and accelerate the development of the Arryx platform for Haemonetics.“
In other agreements/contracts news:
• CardioComm Solutions (Toronto) reported the first Canadian medical center installation of its new GEMS Air wireless ECG management system.
The sale is the first for GEMS Air in Canada, and demonstrates how new wireless technologies are paving the way for more effective management of patients' needs within the community. The applicability for servicing remote regions is the next extension to GEMS Air, according to the company.
Wadea Tarhuni, MD, president/CEO for the Windsor Cardiac Center, said, “This venture means that we can now provide physicians and patients in our region with cutting-edge, technological advances in wireless, continuous heart monitoring. We find that GEMS Air has a high diagnostic yield in detecting paroxysmal atrial fibrillation, which is a major cause of stroke in Canada. According to the Heart and Stroke Foundation, early detection and appropriate therapy of atrial fibrillation can help us prevent 75,000 strokes annually.“
• Mesa Laboratories (Lakewood, Colorado) has signed a strategic distributor agreement with Masy Systems (Pepperell, Massachusetts) to cooperate in market development activities.
The partnership will allow Masy to sell Mesa's DataTrace temperature, humidity and pressure data loggers in the Northeast area of the U.S. Additionally, Masy will begin to use the DataTrace line of data loggers for their validation services and rental businesses going forward. Masy will be primarily adopting the new DataTrace Radio Frequency real-time transmitting loggers for the majority of their services operations. Other aspects of the partnership agreement include joint development of solutions for clients throughout the U.S. and potentially other international regions.